Conference item : Abstract
Neuromyotonia in thymoma-associated myasthenia gravis: a clinico-serological study
- Abstract:
-
Background and aims: Acquired Neuromyotonia (NMT) is an autoimmune condition frequently associated with anti-contactin-associated-protein-like-2 (Caspr2) antibodies. NMT can occur as a paraneoplastic disorder in patients with thymoma, alone or in combination with Myasthenia Gravis (MG). Recently, antibodies against netrin-1-receptors (DCC and UNC5A) have been reported as predictors of thymoma in 6/9 patients with concomitant NMT and MG. We aimed to clinically characterize a large cohort of patients with thymoma-associated MG, and to explore serological correlation of NMT symptoms.
Methods: 268 consecutive patients with thymoma-associated MG were retrospectively collected. NMT was defined as muscle twitching/cramps in at least 2 skeletal districts. Patients with NMT(23) were screened for anti-neuronal antibodies by immunohistochemistry on rat brain and cell based assay.
Results: 23/268 patients developed NMT symptoms (muscle twitching, 3; cramps, 3, or both, 17). Overall, 33/268 patients with thymoma had a tumor recurrence, which was more frequent in those with (8/23) vs those without NMT (25/245, p=0.003). NMT onset preceded the tumor recurrence in 5/6 patients. In univariate analysis predictors of thymoma recurrence were younger age at thymectomy (odds ratio-OR:0.95, confidence interval-CI:0.93-0.97), Masaoka staging (OR:10.73, CI:2.38-48.36) and NMT (OR:4.69, CI:1.76-12.46). 6 patients with NMT had anti-neuronal antibodies (patient#1: Caspr2; patient#2: AMPAR; patient#3: DCC; patient#4: LGI1; patient#5: Caspr2+LGI1+DCC+UNC5A; patient#6: Caspr2+LGI1+DCC). Thymoma recurrence was found less frequently in negative (3/17) vs positive patients with NMT (4/6, #1, #2, #5 and #6; p=0.045).
Conclusion: The occurrence of NMT symptoms in patients with thymoma-associated MG can predict tumor recurrence, and warrants a closer oncologic follow-up. Anti-neuronal surface autoantibodies may be useful to further stratify the recurrence risk.
Disclosure: This work was funded by the ‘Ricerca finalizzata ministeriale 2015-2017’ provided by the Italian ministry of health
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 60.5KB, Terms of use)
-
- Publisher copy:
- 10.1111/ene.13696
Authors
- Publisher:
- Wiley
- Journal:
- European Journal of Neurology More from this journal
- Volume:
- 25
- Issue:
- S2
- Pages:
- 351-351
- Article number:
- EPR1134
- Publication date:
- 2018-06-14
- Acceptance date:
- 2018-04-02
- Event title:
- 4th Congress of the European Academy of Neurology
- Event location:
- Lisbon, Portugal
- Event website:
- https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.13696
- Event start date:
- 2018-06-16
- Event end date:
- 2018-06-19
- DOI:
- EISSN:
-
1468-1331
- ISSN:
-
1351-5101
- Commissioning body:
- European Academy of Neurology
- Language:
-
English
- Keywords:
- Subtype:
-
Abstract
- Pubs id:
-
873350
- Local pid:
-
pubs:873350
- Deposit date:
-
2020-09-15
- ARK identifier:
Terms of use
- Copyright holder:
- European Journal of Neurology
- Copyright date:
- 2018
- Rights statement:
- © 2018 European Journal of Neurology
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Wiley at https://doi.org/10.1111/ene.13696
If you are the owner of this record, you can report an update to it here: Report update to this record